CX3CL1 and neoplasm: It is likely that the PARP inhibitor-mediated activation of the cGAS/STING pathway is responsible for this CX3CL1 induction, as it has also been found in BRCA-deficient tumour cells, causing similar STING activation as PARP inhibitors [16].